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Separation of Serine Proteases
A strategy that allows the modification of the catalytic residue of serine proteases and the
subsequent light-catalysed reactivation has been described (Selective Inhibition, Separation,
and Purification of Serine Proteases: A Strategy Based on a Photoremovable Inhibitor, N.A.
Porter et al., J. Am. Chem. Soc., 121, (1999), 7716-7717). The o-hydroxycinnamate
structures (1) were prepared by either solution or solid-phase techniques and could be used to
react specifically with the key serine hydroxy group of two of the coagulation cascade
enzymes; thrombin and factor Xa.
R3
O
O
OHEt2N
R2 R1
Et2N O O
R3
R3
O
O
Enzyme
OHEt2N
hν + OH Enzyme
(1) (2)
(3)
In particular, the side-chain R2 could be modified to enhance selectivity for serine proteases of
interest. A library of 112 compounds was prepared with different dipeptide residues in this
side-chain, and selective inhibitors for thrombin and factor Xa isolated. With a biotin
derivative in the R3 position, an avidin column could be used to selectively capture either of
the enzymes. A judicious use of inhibition strategy permitted the isolation of each enzyme
from a mixture of the two.
--------------------------------------------------------------------------------------------------------------
Library of Serine and Cysteine Protease Inhibitors
A combinatorial library of 400 compounds based on the cyclohexanone pharmacophore has
been prepared and used to find selective inhibitors of several serine and cysteine protease
inhibitors (Combinatorial Library of Serine and Cysteine Protease Inhibitors That Interact with
Both the S and S’ Binding Sites, P. Abato et al, J. Med. Chem., 42, (1999), 4001-4009). This
pharmacophore allows derivatisation in two directions permitting the introduction of side-
chains that mimic the S2 (Xaa) and S2’ (Yaa) residues of the enzyme’s natural peptide
substrates.
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The library of was prepared using the ‘split synthesis’ approach, using the 20 naturally
occurring amino acids replacing cysteine and methionine with hydroxyproline and ornithine.
The library was subsequently screened against cathepsin B, plasmin, urokinase, kallikrein and
papain, the first four of which have been implicated in the progression of cancer. Amongst the
many active compounds detected following iterative deconvolution of the library, one
component (Xaa = Trp, Yaa = Trp) was found to be a 5µM inhibitor of the serine protease
plasmin.
The data demonstrated that for plasmin, the S2’ subsite prefers to bind hydrophobic and
especially aromatic amino acids. In contrast, the S2’ subsites of cathepsin B and papain do not
appear to have strong preferences for any particular amino acid.
--------------------------------------------------------------------------------------------------------------
Protein Farnesyltransferase Inhibitors
The GTPase, Ras p21, is a molecular switch that fulfils a key function in cellular message
transduction. A large proportion of human tumours including lung, colon and pancreatic
cancers appear to contain a Ras mutant that is permanently in the ‘on’ state. As prenylation
catalysed by protein farnesyltransferase (FTase) is an essential Ras post-translational
modification, there has been much interest in the discovery of inhibitors of this enzyme as
anticancer agents.
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Building on known active FTase inhibitor structures, combinatorial library chemistry has been
employed in the discovery of novel and more potent inhibitors (Discovery of a Series of
Cyclohexylethylamine-Containing Protein Farnesyltransferase Inhibitors Exhibiting Potent
Cellular Activity, K.J. Henry et al., J. Med. Chem., 42, (1999), 4844-4852). Using the known
inhibitor, FTI-276 (5) as a starting point, a library of benzylic amines was prepared via the
reductive amination of a resin-bound aldehydic intermediate, followed by TFA-catalysed
cleavage from the resin. The preferred compound from this series (6) is a nanomolar inhibitor
of FTase. Orthodox solution-phase medicinal chemistry has been employed to generate potent
analogues that have been demonstrated to attenuate tumour growth in a nude mouse xenograft
model of human pancreatic cancer.
